Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors

被引：0

作者：

Drilon, A. ^{[1
]}

Besse, B. ^{[2
]}

Camidge, D. R. ^{[3
]}

Ou, S. H. I. ^{[4
]}

Gadgeel, S. M. ^{[5
]}

Johnson, M. L. ^{[6
]}

Calles, A. ^{[7
]}

de Miguel, M. J. ^{[8
]}

Spira, A. I. ^{[9
]}

Felip, E. ^{[10
]}

Lopes, G. ^{[11
]}

van der Wekken, A. J. ^{[12
,13
]}

Elamin, Y. Y. ^{[14
]}

Green, J. ^{[15
]}

Sun, Y. ^{[16
]}

Soglia, J. ^{[17
]}

Zhu, V. W. ^{[15
]}

Lin, J. J. ^{[18
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Early Drug Dev Serv, New York, NY USA

[2] Inst Gustave Roussy, Canc Med, Villejuif, France

[3] Univ Colorado Canc Ctr, Thorac Oncol, Anschutz Med Campus, Aurora, CO USA

[4] Univ Calif Irvine, Med, Med Ctr, Orange, CA USA

[5] Henry Ford Canc Inst, Internal Med, Detroit, MI USA

[6] Sarah Cannon Res Inst, Oncol, Nashville, TN USA

[7] Hosp Univ Gregorio Maranon, Med Oncol, Madrid, Spain

[8] START Madrid HM CIOCC, Med Oncol, Madrid, Spain

[9] Virginia Canc Specialists, Thorac & Phase I Program, NEXT Oncol, Fairfax, VA USA

[10] Hosp Valle De Hebron, Oncol, Barcelona, Spain

[11] Univ Miami Miller, Sch Med, Sylvester Comprehens Canc Ctr, Med Oncol Thorac Med Oncol, Miami, FL USA

[12] Univ Groningen, Groningen, Netherlands

[13] Univ Med Ctr Groningen, Pulm Oncol, Groningen, Netherlands

[14] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA

[15] Nuvalent Inc, Clin Dev, Cambridge, MA USA

[16] Nuvalent Inc, Biol, Cambridge, MA USA

[17] Nuvalent Inc, Translat Dev, Cambridge, MA USA

[18] Massachusetts Gen Hosp, Med, Boston, MA USA

来源：

EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S6 / S7

页数：2

共 50 条

[1] NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study
Drilon, A.
Ou, S. -H. I.
Gadgeel, S.
Johnson, M.
Spira, A.
Lopes, G.
Besse, B.
Felip, E.
van der Wekken, A. J.
Calles, A.
de Miguel, M. J.
Camidge, D. R.
Elamin, Y.
Liu, S.
Bauman, J.
Haggstrom, D.
Riley, G.
Pelish, H. E.
Zhu, V. W.
Lin, J. J.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S416
[2] Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study
Besse, B.
Johnson, M.
Ou, S-H. I.
Gadgeel, S.
Spira, A.
Lin, J.
Felip, E.
van der Wekken, A. J.
Calles, A.
de Miguel, M. J.
Camidge, D. R.
Elamin, Y.
Lopes, G. D. L.
Liu, S.
Bauman, J.
Haggstrom, D.
Riley, G.
Pelish, H. E.
Zhu, V. W.
Drilon, A.
ANNALS OF ONCOLOGY, 2022, 33 : S68 - S69
[3] Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours
Besse, B.
Drilon, A. E.
Cho, B. C.
Camidge, D. R.
Neal, J.
Lin, C-C.
Liu, S. V.
Nagasaka, M.
Kao, S. C-H.
Felip, E.
Van der Wekken, A. J.
Lin, C. C.
Bauman, J. R.
Gadgeel, S.
Samant, M.
Shen, J.
Sun, Y.
Zhu, V. W.
Upadhyay, V. A.
Lin, J. J.
ANNALS OF ONCOLOGY, 2024, 35 : S804 - S805
[4] Safety and Preliminary Clinical Activity of Ropotrectinib ( TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC
Lin, J.
Kim, D.
Drilon, A.
Doebele, R.
Lee, J.
Zhu, V.
Ahn, M.
Lim, J.
Stopatschinskaja, S.
Cui, J. J.
Hyman, D.
Camidge, R.
Ou, S.
Shaw, A.
Cho, B. C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S322 - S322
[5] Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
Drilon, A.
Cho, B. C.
Kim, D. -W.
Lee, J.
Lin, J. J.
Zhu, V.
Camidge, R. D.
Stopatschinskaja, S.
Cui, J. J.
Hyman, D. M.
Ou, S. -H.
Shaw, A. T.
Doebele, R. C.
ANNALS OF ONCOLOGY, 2019, 30
[6] NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Drilon, Alexander
Horan, Joshua C.
Tangpeerachaikul, Anupong
Besse, Benjamin
Ou, Sai-Hong Ignatius
Gadgeel, Shirish M.
Camidge, D. Ross
Wekken, Anthonie J. van der
Nguyen-Phuong, Linh
Acker, Adam
Keddy, Clare
Nicholson, Katelyn S.
Yoda, Satoshi
Mente, Scot
Sun, Yuting
Soglia, John R.
Kohl, Nancy E.
Porter, James R.
Shair, Matthew D.
Zhu, Viola
Davare, Monika A.
Hata, Aaron N.
Pelish, Henry E.
Lin, Jessica J.
CANCER DISCOVERY, 2023, 13 (03) : 598 - 615
[7] Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours
Lassen, Ulrik
LANCET ONCOLOGY, 2020, 21 (02): : 193 - 194
[8] Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
Lin, Jessica J.
Langenbucher, Adam
Gupta, Pranav
Yoda, Satoshi
Fetter, Isobel J.
Rooney, Marguerite
Do, Andrew
Kem, Marina
Chang, Kylie Prutisto
Oh, Audris Y.
Chin, Emily
Juric, Dejan
Corcoran, Ryan B.
Dagogo-Jack, Ibiayi
Gainor, Justin F.
Stone, James R.
Lennerz, Jochen K.
Lawrence, Michael S.
Hata, Aaron N.
Mino-Kenudson, Mari
Shaw, Alice T.
NPJ PRECISION ONCOLOGY, 2020, 4 (01)
[9] Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
Jessica J. Lin
Adam Langenbucher
Pranav Gupta
Satoshi Yoda
Isobel J. Fetter
Marguerite Rooney
Andrew Do
Marina Kem
Kylie Prutisto Chang
Audris Y. Oh
Emily Chin
Dejan Juric
Ryan B. Corcoran
Ibiayi Dagogo-Jack
Justin F. Gainor
James R. Stone
Jochen K. Lennerz
Michael S. Lawrence
Aaron N. Hata
Mari Mino-Kenudson
Alice T. Shaw
npj Precision Oncology, 4
[10] Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Liu, Dazhi
Offin, Michael
Harnicar, Stephen
Li, Bob T.
Drilon, Alexander
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1247 - 1252

← 1 2 3 4 5 →